Sonova News from AudiologyNOW! 2012
Innovation leadership continues
Lyric - The new Lyric generation available to more people
Phonak presents the new generation Lyric, a 100% invisible and extended wear hearing aid. In developing a new generation of Lyric devices, Phonak reduced the size of the hearing aid and thereby increased the anatomical fit rate by 50%. Lyric can be worn for up to four months without removing the device or changing batteries. Positioned close to the eardrum, Lyric makes use of the anatomical function of the pinna and offers natural sound quality and excellent wearing comfort.
Essential - Spice+ technology now available in four performance levels
Phonak is introducing its new performance level, Essential, based on the Spice+ technology. The new Essential products provide state-of-the-art Spice+ features at a very competitive price. Essential includes a new product family named Phonak Dalia as well as an entry-level model of the award-winning Audéo S SMART I and Naída S I. With this new performance level, Phonak meets the needs of end-users who are seeking value for money products without compromising on latest technology and state-of-the-art features.
Quantum Pro and Moxi Pro - Unitron's new premium products
Unitron announces the introduction of the new premium hearing instruments for its Quantum(TM) and Moxi(TM) product families. Built on Era(TM) , Unitron's latest generation platform, Quantum Pro and Moxi Pro deliver innovative binaural spatial processing and SpeechZone(TM) to enrich clients' hearing experience and speech understanding, even in the most challenging listening environments. Unitron also presented the uDirect(TM) 2 and uTV(TM) 2 accessories.
Quantum micro CIC - The tiny custom product
The Quantum family of custom products was expanded to include a tiny custom micro CIC. It is the tiniest Quantum ever delivered, yet continues to provide high-fidelity natural sound. It is a great hearing instrument for a first time wearer, offering a fully automatic, natural listening experience and fit right from the start.
ClearVoice(TM) - The industry's only Speech Enhancement Technology
Advanced Bionics (AB) announced on March 19, 2012 the FDA approval of ClearVoice(TM) in the United States. ClearVoice(TM) is already approved for use in Europe, Asia and Canada. Built on AB's proprietary HiRes Fidelity 120(TM) * technology for high-performance hearing, ClearVoice(TM) has been designed to automatically analyze and adapt to each listening situation encountered throughout the day of a cochlear implant wearer, separating the distracting noises from speech so that communication can be a truly effortless experience. ClearVoice(TM) is the first and only speech enhancement technology available in the cochlear implant market, further solidifying AB's position as the industry's innovation leader. (*Not yet approved for pediatric use in the United States.)
For further information about the products, please find below the trade press releases of the respective brands.
This Media Release may contain forward-looking statements which offer no guarantee with regard to future performance. These statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside the company's control.
Sonova Holding AG
Sonova is the leading provider of innovative hearing healthcare solutions. The globally active group is the world's top manufacturer of hearing systems, the market leader in wireless communication systems for audiology applications, develops and manufactures advanced cochlear implant systems and provides professional solutions for hearing protection. Sonova is pursuing a clear growth strategy and is intent to grow faster than the market. To this end it is constantly expanding its existing business segments and branching out into other areas of the hearing healthcare industry. Present in over 90 countries, and with a workforce of over 7,800 employees, Sonova generated sales of CHF 1.6 billion in the financial year 2010/11 and a net profit of CHF 231 million. This financially strong group of companies bases its success on innovation, customer focus and proactive cost management. The company has been successfully promoting understanding and communication for over 60 years, and is ideally positioned to benefit from the trends in this growth industry.
For more information please visit www.sonova.com.
Sonova shares (ticker symbol:SOON) have been listed on the SIX Swiss Exchange since 1994. The securities of Sonova have not been and will not be registered under the U.S. Securities Act and may not be offered or sold in the United States of America except pursuant to an exemption from the registration requirements under the U.S. Securities Act, or outside the United States of America in reliance on Regulation S under the U.S. Securities Act.